BRUSSELS (Reuters) – The European Union is negotiating early procurement agreements for vaccines opposed to COVID-19 with the Modern Drug Brands (MRNA). Sanofi (SASY.PA) and Johnson and Johnson (JNJ. N) as with BioNtech biotech corporations (BNTX. O) and CureVac, two European resources were told to Reuters.
Talks are adhering to an agreement reached in June through 4 EU member states with AstraZeneca (AZN). L) for the initial acquisition of 400 million doses of its future COVID-19 vaccine, in the precept to be taken in the 27 EU countries.
Information on ongoing talks shared through the European Commission, the EU’s executive arm, with EU fitness ministers at a meeting in Berlin on Thursday, resources said.
The talks verify the bloc’s strongest stance on acquiring vaccines and potential drugs for COVID-19 after america’s early efforts to discharge promising remedies and vaccines.
“We are in talks with several vaccine corporations opposed to COVID-19,” a Commission spokesman said Friday, who did not want to comment on the corporations expressed because the negotiations were confidential.
More than 150 vaccines imaginable worldwide are being developed and tested in an attempt to prevent the pandemic. Of 23 human clinical trials, at least 3 are in the final phase of Test III, adding applicants for Sinopharm and Sinovac Biotech (SVA). AstraZeneca and Oxford University in China.
The most complex European talks appear to be those of Johnson and Johnson and Sanofi, confirming a Reuters report in June, as the EU is already discussing main points on the amount of doses needed.
The EU is negotiating a two-hundred million-dose source of its eventual vaccine with US giant Johnson and Johnson, resources said, and added that other materials could also be available.
The block also plans to secure three hundred million doses of the future vaccine developed through France’s Sanofi in cooperation with British drug manufacturer GlaxoSmithKline Plc (GSK) at the time of next year. L), the resources said.
When asked about the negotiations, Sanofi told Reuters in “advanced talks with the EU for the delivery of three hundred million doses.”
Sources were also ongoing, according to sources, with the US company Moderna, whose experimental COVID-19 vaccine showed this week that it caused immune responses in the forty-five healthy volunteers in an early-stage ongoing study, according to US researchers.
Later on Friday, Moderna showed it in talks with European countries about his possible vaccine, but said at this level that he had no agreement to announce.
The EU is also in talks with German biotech corporations BioNtech and CureVac to buy their vaccines in advance, according to resources. The two corporations, already presented with the EU budget to expand their plans, declined to comment.
BioNtech is preparing a possible COVID-19 vaccine in cooperation with US pharmaceutical giant Pfizer (PFE). N), for which one hundred million doses can be obtained until the end of the year.
CureVac is a pioneer in the so-called messenger RNA approach, which is applied through BioNTech and Modern.
RNA molecules are uns married chain versions of the double helix of DNA that can be produced in an undeniable biochemical process.
EU-led talks are conducted through determined negotiators through an guidance organisation in which all 27 EU states are represented.
Once the agreements are concluded, EU states can place orders with brands of medicines to ensure exact quantities for their populations.
If effective vaccine doses were not sufficient to cover the entire EU population, vaccines would be distributed on the basis of demographic and epidemiological data, the Commission said.
A third EU source said the bloc also renegotiated the AstraZeneca agreement between Germany, France, Italy and the Netherlands to ensure that all EU states had equivalent access to the guaranteed doses in the original agreement.
The source said the discussion was supported by the 4 states that signed the first agreement.
Reporting through Francesco Guarascio with more reports through Matthias Blamont in Paris, Caroline Copley in Berlin, Kate Kelland in London and Julie Steenhuysen; edited through Nick Macfie / Mark Heinrich
All quotes were delayed for at least 15 minutes. See here for a complete list of operations and delays.
© 2020 Reuters. All rights are reserved.